BECLOMETHASONE DIPROPIONATE EASYHALER® IS AS EFFECTIVE AS BUDESONIDE TURBOHALER® IN THE CONTROL OF ASTHMA AND IS PREFERRED BY PATIENTS

Lukas R. Jäger, Kari Laurikainen, M. Leinonen, M Silvasti

International Journal of Clinical Practice · 2000 · 15 citations · 11 references

DOIFull text

Open access

Concepts

Abstract

SUMMARY This randomised, crossover study compared the efficacy, safety, acceptability and patient preference of two multidose powder inhalers (MDPIs) – beclomethasone dipropionate Easyhaler® (BDP‐EH) and budesonide Turbohaler® (BUD‐TH) – in 79 stable asthmatics who used inhaled steroids but had no experience of MDPIs. After eight weeks' treatment a mean increase in morning PEF of 16 l/min from a baseline of 356 ±112 l/min was observed for each treatment. Similar improvements occurred in evening PEF, FEV 1 , FVC and asthma symptoms. Both treatments had only minimal effect on morning serum Cortisol levels. Compliance with both treatments was high (>97%) but almost twice as many patients favoured the EH (59%) compared with the TH (33%); 7% rated the devices equally. Scores of device acceptability were significantly in favour of the EH (p=0.001). BDP‐EH and BUD‐TH showed comparable efficacy and safety in the treatment of asthma. Each MDPI had a high rate of compliance, but patients registered greater preference for the EH than the TH. ( Int J Clin Pract 2000; 54(6): 368‐372)

References

11